ALL - CAR-T: Alternative targets and age groups
LINKS TO ABSTRACTS:
Presentation ID p403-1
Presenter: Jing Pan, Beijing, China
The study authors report the initial toxicity profile and anti-leukemia activity of a donor-derived CD7- targeted cellular immunotherapy for patients with relapsed or refractory T-ALL.
Presentation ID p403-2
Presenter: Sara Ghorashian, United Kingdom
The study authors conclude that their cohort with predominantly MLL-rearranged leukemia, represents the largest series of children aged under 3 treated with tisagenlecleucel. The median age at infusion was 17 months. It was feasible to leucapherese and manufacture a product in 90%. The MRD negative CR/CRi response, 6 and 12 months EFS, and OS rates were equivalent to those of patients on the ELIANA study (median age 11 years). The toxicity profile i.e. rates of severe CRS, neurotoxicity, and cytopenias were broadly similar, as were rates of hypogammaglobulinemia and infection. The rates of relapse and CD19- relapses were also similar to real-world data from the US, France, and UK.
The study authors highlight the fact that it was a cohort of very high-risk patients with predominantly infant ALL, traditionally a disease entity with very poor outcomes. The remarkably good EFS and OS documented strongly support the use of tisagenlecleucel in the youngest children, even in the setting of very high-risk infant ALL.
Presentation ID p403-3
Presenter: Bijal Shah, United States
The study authors conclude that After a median follow-up of 16.4 months, KTE-X19 demonstrated compelling clinical benefit in heavily pretreated adults with R/R B-ALL. The median overall survival was not yet reached for responding patients. There was a manageable safety profile.
Presentation ID p403-4
Presenter: Peihua Lu, Langfang, China
The study authors conclude that their study demonstrates the superiority of dual STAR-T in its anti-tumor potency compared to conventional CAR-T in an animal model. The CD19/CD20 STAR-T demonstrated technical feasibility and the ability to achieve a high CR with low toxicity in a phase I study of R/R B-ALL. The authors see a potential for future development for solid tumors.
Presentation ID p403-5
Presenter: Kaiting Tang, China
The study authors conclude that sequential CD19-22 CAR T cell therapy can achieve promising long-term outcomes with a 2-year LFS of 60% in pediatric patients with r/r B-ALL without post-CAR transplantation. Early Ig recovery has a high risk of relapse.